Alvogen Pharma US Inc. has arranged a new private loan led by Centerbridge Partners that will ease near-term refinancing pressure as the generic drugs maker grapples with projected revenue declines.
Blue Torch Capital also participated in the deal, which will refinance the company’s syndicated loan that had been due to be repaid this year, said the people, who asked not to be identified as they’re not authorized to speak publicly. The new financing, the size of which couldn’t be immediately determined, will extend Alvogen’s debt by three to four years, one of the people said.
Alvogen had a roughly $727 ...
